Disaggregation of high-molecular weight species during downstream processing to recover functional monomer

Purification of Modified Therapeutic Proteins Available on the Market: An Analysis of Chromatography-Based Strategies

Proteins, which have inherent biorecognition properties, have long been used as therapeutic agents for the treatment of a wide variety of clinical indications. Protein modification through covalent attachment to different moieties improves the therapeutic's pharmacokinetic properties, affinity, stability, confers protection against proteolytic degradation, and increases circulation half-life. Nowadays, several modified therapeutic proteins, including PEGylated, Fc-fused, lipidated, albumin-fused, and glycosylated proteins have obtained regulatory approval for commercialization. During its manufacturing, the purification steps of the therapeutic agent are decisive to ensure the quality, effectiveness, potency, and safety of the final product. Due to the robustness, selectivity, and high resolution of chromatographic methods, these are recognized as the gold standard in the downstream processing of therapeutic proteins. Moreover, depending on the modification strategy, the protein will suffer different physicochemical changes, which must be considered to define a purification approach. This review aims to deeply analyze the purification methods employed for modified therapeutic proteins that are currently available on the market, to understand why the selected strategies were successful. Emphasis is placed on chromatographic methods since they govern the purification processes within the pharmaceutical industry. Furthermore, to discuss how the modification type strongly influences the purification strategy, the purification processes of three different modified versions of coagulation factor IX are contrasted.

Characterization of Fc-fusion protein aggregates derived from extracellular domain disulfide bond rearrangements

Aggregation of protein biotherapeutics has consequences for decreasing production and has been implicated in immunogenicity. The mechanisms of protein aggregation vary depending on the protein and the expression system utilized, making it difficult to elucidate the conditions that promote their formation. Nonnative aggregation of recombinant immunoglobulin G protein therapeutics from mammalian expression systems has been extensively studied. To better understand the mechanisms behind aggregation of glycosylated fusion proteins produced in Chinese hamster ovarian cells, we have examined the high-molecular-weight (HMW) species of activin receptor-like kinase 1 Fc fusion protein. Size-exclusion chromatography and sodium dodecyl sulfate-polyacrylamide gel electrophoresis indicate that two populations of aggregate exist: (1) nondisulfide-linked, higher-order aggregates and (2) disulfide-linked oligomers. The largest aggregated species have increased nonnative structure, whereas the smallest aggregated species maintain structure similar to monomer. The HMW species display decreased levels of O-linked glycosylation, higher occupancy of high-mannose N-linked oligosaccharide structures, and overall less sialylation as their size increases. Disulfide-linked aggregate species were found to associate through the extracellular domain. N-linked glycosylation on the extracellular domain (ECD) appears to discourage disulfide-linked aggregation. Elucidation of the specific mechanisms behind disulfide-linked aggregate formation may assist in designing processes that limit aggregate formation in cell culture, with implications for increased production.